Meda AB (publ) extraordinary general meeting bulletin

At the extraordinary general meeting (EGM) on November 6, 2014 of Meda AB (publ), it was resolved to approve the board of director’s resolution as of October 10, 2014, to launch a rights issue of shares of series A shares with preferential rights for Meda’s shareholders. The purpose of the rights issue is to finance part of the acquisition of Rottapharm.

According to the terms for the rights issue shareholders in Meda will have preferential rights to subscribe for one (1) new share of series A for each ten (10) shares held in Meda at the record date. In addition, investors are given the opportunity to subscribe for shares without preferential rights. The subscription price is SEK 61 per share, which means that the rights issue will provide Meda with a maximum of approximately SEK 2,027 million, before issue expenses, through the issue of no more than 33,224,306 new shares of series A. The record date is November 13, 2014. This means that the share will be traded exclusive of preferential rights as of November 12, 2014. The subscription period will run from November 19, 2014 up to and including December 4, 2014, or such later date as decided by the board of directors.

Further, the EGM resolved, in accordance with the nomination committee’s proposal, that the number of board members of Meda shall be increased by one and amount to nine until the end of the next Annual General Meeting, that board remuneration for the newly elected board member shall amount to SEK 225,000 until the end of the next Annual General Meeting and to elect Luca Rovati, the representative for the second largest shareholder in Meda, Fidim S.r.l., as new board member and Deputy Chairman of Meda.

The EGM resolutions are available at Meda’s head office at Pipers väg 2A, Solna, Sweden, tel. +46 8 630 1900. They will be sent on request free of charge to shareholders who provide an address.

For further inquiries, please contact:

Paula Treutiger, VP Corporate Communications & Sustainability                                     ph: +46 733-666 599                                                                                                                                                                                                        

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organizations in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Find out more, visit

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.